Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.1%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was down 3.1% on Wednesday . The stock traded as low as $0.64 and last traded at $0.66. Approximately 1,675,141 shares were traded during trading, an increase of 93% from the average daily volume of 867,677 shares. The stock had previously closed at $0.68.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a research report on Wednesday, February 14th.

Citius Pharmaceuticals Trading Down 3.1 %

The stock has a market capitalization of $105.53 million, a PE ratio of -2.55 and a beta of 1.54. The business’s 50 day moving average is $0.78 and its 200 day moving average is $0.76.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Wednesday, February 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.19). As a group, analysts anticipate that Citius Pharmaceuticals, Inc. will post -0.21 EPS for the current year.

Institutional Trading of Citius Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its holdings in shares of Citius Pharmaceuticals by 88.5% in the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares during the period. SG Americas Securities LLC bought a new stake in Citius Pharmaceuticals during the 3rd quarter valued at $39,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Citius Pharmaceuticals in the 3rd quarter worth $76,000. Finally, Wealth Advisory Solutions LLC bought a new position in shares of Citius Pharmaceuticals during the 1st quarter worth $135,000. 16.88% of the stock is currently owned by institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.